Boehringer Options Six China Originated Oncology Programs
Sino Biopharmaceutical and Boehringer Ingelheim announced a six-program ADC and T-cell engager option-and-license collaboration on November 4. The disclosed $358 million is upfront plus near-term payments; $7 billion is contingent option, development, regulatory and…
